Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on January 8, 2018, regarding events occurring on January 2, 2018. The company is a Delaware corporation incorporated in Israel, operating in the biotechnology sector.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Under Item 5.02, the Board of Directors announced the following changes:
- Resignation: Professor Youssef Av-Gay resigned from the Board of Directors on January 2, 2018.
- Election: Yoori Lee was elected as a director to replace Professor Av-Gay on January 2, 2018.
Management Commentary and Background
Management selected Ms. Lee due to her extensive consulting experience and knowledge of the biotechnology industry. Her background includes:
- Co-Founder and President of Trio Health Advisory Group, Inc. (since January 2013).
- Former Managing Director and Director of MEDACorp Services at Leerink Partners LLC (February 1996 to January 2011).
The filing does not contain guidance, outlook, risks, contingencies, or unusual items beyond the board composition change.
Investor Verification Checklist
- Verify the effective date of Yoori Lee's directorship and Youssef Av-Gay's resignation.
- Confirm the company's current ticker symbol and trading status, noting the discrepancy between the requested company name (Beyond Air) and the filing registrant (AIT Therapeutics).
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.